If implemented, SCR005 mandates that starting with the 2027 plan year, PEHP will include at least one clinically appropriate non-opioid prescription drug for every opioid prescription drug. Furthermore, the resolution limits cost-sharing, prior authorization, and other barriers that are often more severe for non-opioid medications compared to their opioid counterparts. These changes are intended to facilitate easier access to non-opioid medications, potentially reducing reliance on opioids and addressing the coverage disparities currently present in the health insurance framework for employees.
Summary
SCR005, known as the Concurrent Resolution Directing PEHP Regarding Pain Medication, was introduced in response to the opioid epidemic that has significantly impacted Utah. This resolution seeks to address the accessibility of non-opioid pain medications within the Public Employees' Benefit and Insurance Program (PEHP) for state employees. The resolution underscores the need for a shift towards non-opioid therapies as a primary treatment option for chronic pain, aligning with guidelines from the Centers for Disease Control and Prevention that recommend such alternatives in order to mitigate opioid dependency and its associated harms.
Sentiment
The sentiment around SCR005 has been largely positive, highlighting a growing awareness and concern regarding the opioid crisis. Legislators have expressed support for the resolution as a necessary step to ensure state employees have easier access to safer pain management alternatives. The resolution aligns with a broader public health initiative to promote non-opioid treatments and reflects a commitment to address the opioid crisis effectively.
Contention
While the resolution has garnered support, there may be challenges in its execution, particularly regarding funding and the compliance of health plans in making necessary adjustments. The bill allocates an initial amount of $150,000 for its implementation, with a provision to request additional funding if needed. A point of contention may arise if there are insufficient resources to effectively expand the formulary or if PEHP faces difficulties in negotiating with pharmaceutical suppliers. Addressing these challenges will be crucial to the successful realization of the objectives outlined in SCR005.